KRAS and neoplasm: For this, we used a model of aggressive CRC grown from mouse tumor organoids (MTO) carrying compound genetic alterations (Apc, Kras, Trp53, Tgfbr2) injected into the caecum wall of immunocompetent C57BL/6J mice (see “Methods”)17.